Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
AstraZeneca is a big drug company that discovers, makes, and sells prescription medicines for cancer, heart and lung disease, and other serious illnesses.
AstraZeneca is one of the world's largest pharmaceutical companies — a maker of prescription drugs that treat cancer, heart and kidney disease, lung problems like asthma, and rare metabolic disorders. It does not sell to you directly. Its customers are doctors and hospitals, plus governments and insurers that ultimately pay for the medicine, and the company's job is to convince them that its drugs work better than the alternatives.
The business runs on a simple but brutal engine. Researching a new drug takes years and costs hundreds of millions, and most experiments fail before anything reaches a pharmacy shelf. When one succeeds, the company patents it, and for roughly a decade it holds the exclusive right to sell it — which is where the real money is. A single best-selling medicine can pull in billions of dollars a year. Then the patent expires, cheap copies flood the market, and that river of cash slows to a trickle. So AstraZeneca lives and dies by whether its pipeline of new drugs is bigger than the pile of old ones losing protection. Cancer is its biggest and fastest-growing area, and its lung-cancer drug Tagrisso plus a set of medicines built with Japan's Daiichi Sankyo have become central to the story. The company also sells Farxiga, a diabetes drug that turned out to protect the heart and kidneys too, alongside its older respiratory medicines. It has deep roots in Britain — headquarters in Cambridge, with major research and manufacturing sites around the world — and a huge share of its sales come from the United States, which makes it sensitive to American drug-pricing politics.
Astra began in Sweden as a small drugmaker with a simple problem to solve: making medicines people could trust, close to home. Its big break came with Xylocaine, a numbing drug that won approval in America in the 1950s and became a favorite of doctors there. That one product turned a domestic manufacturer into a serious player — and hinted that Astra's real future lay beyond Sweden's borders.
Decades later, the British chemical giant ICI decided its chemical business and its drug business were better off apart. It split out the pharmaceutical side as Zeneca, giving the medicine people their own company and their own shot at growth.
Then came the big move: Sweden's Astra and Britain's Zeneca joined forces, one of the largest merges ever between two European companies. The logic was simple — each side had strengths the other lacked, and together they could push science further. The deal created a new name: AstraZeneca.
To keep growing, the company bought the biotech firm MedImmune, betting on a newer kind of medicine called biologics — drugs made from living cells rather than chemicals. The price looked steep to many, and the deal was second-guessed for years. But it quietly built the pipeline the company would lean on later.
By the early 2010s, AstraZeneca was in trouble: key patents were expiring, cheaper copies were eating its sales, and some drugs had failed. Investors were furious, and CEO David Brennan stepped down just hours before a shareholder meeting. In came Pascal Soriot from Roche — a hire that would reshape the whole company.
Soon after, the American giant Pfizer tried to buy AstraZeneca outright, a deal that would have created the biggest drug company in the world. AstraZeneca said no, arguing it was worth more than the offer — a bold bet that its own future profits would beat the cash on the table. The rivalry and the spotlight would shape both companies for years.
When COVID-19 hit, AstraZeneca teamed up with the University of Oxford to make a vaccine — and promised to supply it at cost during the pandemic, not for profit. Doses reached billions of people around the world, making it one of the biggest public health contributions in the industry's history.
AstraZeneca then spent a huge sum on Alexion, a maker of rare-disease drugs with blockbusters Soliris and Ultomiris. The deal added a third leg to the business alongside cancer and biopharma, and pushed the company into rare diseases for the first time. It was a big, expensive bet that broadened what AstraZeneca was.
Later, after some clinical setbacks and a reported merger with Bristol Myers Squibb that fell through, AstraZeneca launched a three-year plan to trim costs and pour the savings back into its pipeline. CEO Soriot stood by his goal of reaching $80 billion in annual sales by 2030, pointing to more than 180 projects in development. The message was clear: cut where needed, but keep betting on the science.
One of its smartest moves didn't happen in a lab. In 2020, as the pandemic hit, AstraZeneca partnered with Oxford University spinoff Vaccitech on a cheap, easy-to-store COVID vaccine and sold it at cost during the crisis — a gift to the world that also made the company a household name. That same instinct for dealmaking shows elsewhere: it bought Alexion, a rare-disease specialist, for about $39 billion in 2021 to diversify away from patent cliffs. And in 2024 it announced plans to build a big manufacturing plant in Singapore for antibody-drug conjugates — a clever class of cancer drugs that act like guided missiles, delivering poison straight to tumor cells — betting that this is where the next wave of profits will come from.
Saved answer · last researched 23 Oct 2026